Managing Adverse Effects of Incretin-Based Medications for Obesity
Authors:
- 2 September 2025
- journal article
- Published by American Medical Association (AMA) in JAMA
- Vol. 334 (9) , 822
Abstract
This JAMA Insights explores optimal strategies for managing the adverse effects associated with incretin-based medications for obesity, including semaglutide and tirzepatide.Keywords
This publication has 10 references indexed in Scilit:
- Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or ObesityJAMA Network Open, 2025
- Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity CareJournal of the Academy of Nutrition and Dietetics, 2024
- Physical Activity and Excess Body Weight and Adiposity for Adults. American College of Sports Medicine Consensus StatementMedicine & Science in Sports & Exercise, 2024
- Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesityObesity Reviews, 2024
- Medications for ObesityJAMA, 2024
- Nutritional considerations with antiobesity medicationsObesity, 2024
- New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based TherapeuticsAnnual Review of Medicine, 2023
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extensionDiabetes, Obesity and Metabolism, 2022
- Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statementClinical Nutrition, 2022
- Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practicePostgraduate Medicine, 2021